Abstract
The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Current HIV Research
Title: Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count
Volume: 6 Issue: 1
Author(s): Claudio M. Mastroianni, Miriam Lichtner, Raffaella Rossi, Maria C. Rizza, Fabio Mengoni, Ilaria Sauzullo, Anna P. Massetti, Giuseppe Luzi, Anne Hosmalin and Vincenzo Vullo
Affiliation:
Keywords: HIV, dendritic cells, antiretroviral therapy, innate immunity, CD4, pDC
Abstract: The depletion in circulating dendritic cells (DCs) and inverse correlation with viral load have been described in human immunodeficiency virus (HIV)-infected patients. The aim of this study was to investigate whether the DC blood count in antiretroviral-treated patients might be predictive of viral load control independent of CD4+ T cell count. Plasmacytoid DCs (pDCs) and myeloid DCs (mDCs) were enumerated using a newly developed flow cytometric assay based on TruCOUNT. A significant reduction of circulating pDCs and mDCs was detected both in untreated and -treated subjects. The probability of experiencing viral load increase according to pDC, and CD4 count at baseline was evaluated in 39 treated patients. Individuals with lower baseline pDCs were more likely to have an increase of HIV-RNA during the 30 month follow-up in comparison with patients with high pDCs (p < 0.001). In particular, the pDC measurement may be useful in the context of a high CD4 count, to distinguish the patients who have virological failure despite high CD4 counts. These findings suggest that in treated patients the enumeration of circulating DCs, especially pDC count, can augment the predictive value of CD4 measurement in predicting virologic failure.
Export Options
About this article
Cite this article as:
Mastroianni M. Claudio, Lichtner Miriam, Rossi Raffaella, Rizza C. Maria, Mengoni Fabio, Sauzullo Ilaria, Massetti P. Anna, Luzi Giuseppe, Hosmalin Anne and Vullo Vincenzo, Plasmacytoid Dendritic Cells Count in Antiretroviral-Treated Patients is Predictive of HIV Load Control Independent of CD4+ T-Cell Count, Current HIV Research 2008; 6 (1) . https://dx.doi.org/10.2174/157016208783571937
DOI https://dx.doi.org/10.2174/157016208783571937 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Implication of Nanofibers in Oral Drug Delivery
Current Pharmaceutical Design Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets The Use of Mesenchymal Stem Cells for the Treatment of Autoimmunity: From Animals Models to Human Disease
Current Drug Targets Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Role of FoxP3<sup>+</sup> Treg Cells Mediating Immune Suppression in Leprosy
Current Immunology Reviews (Discontinued) Immuno-Modulatory Properties of a Quinolin-2-(1H)-on-3-Carboxamide Derivative: Relevance in Multiple Sclerosis
Recent Patents on CNS Drug Discovery (Discontinued) Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Measurement of Palmitoylethanolamide and Other N-Acylethanolamines During Physiological and Pathological Conditions
CNS & Neurological Disorders - Drug Targets The Prospect of Stem Cells as Multi-Faceted Purveyors of Immune Modulation, Repair and Regeneration in Multiple Sclerosis
Current Stem Cell Research & Therapy Chebulagic Acid Synergizes the Cytotoxicity of Doxorubicin in Human Hepatocellular Carcinoma Through COX-2 Dependant Modulation of MDR-1
Medicinal Chemistry Insights into Ebola Virus VP35 and VP24 Interferon Inhibitory Functions and their Initial Exploitation as Drug Targets
Infectious Disorders - Drug Targets A Novel Cell-based <i>In vitro</i> Assay for Antiviral Activity of Interferons α, β, and γ by qPCR of MxA Gene Expression
Recent Patents on Biotechnology Giardiasis: Recent Progress in Chemotherapy and Drug Development (Hot Topic: Anti-Infective Agents Executive Editors: Mitchell A. Avery / Vassil St.) Georgiev
Current Pharmaceutical Design Acknowledgment to Reviewers
Recent Patents on Inflammation & Allergy Drug Discovery Placental Cytokines in the Pathogenesis of Preeclampsia and Hellp Syndrome
Current Women`s Health Reviews PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) What’s Old is New Again – A Review of the Current Evidence of Colchicine in Cardiovascular Medicine
Current Cardiology Reviews Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Non-Invasive Tests in Animal Models and Humans: A New Paradigm for Assessing Efficacy of Biologics Including Prebiotics and Probiotics
Current Pharmaceutical Design ADAM8/MS2/CD156, an Emerging Drug Target in the Treatment of Inflammatory and Invasive Pathologies
Current Pharmaceutical Design